FOLR1 expression

News alerts, weekly reports and conference planners

Entrez ID:

2348

Related biomarkers:

Expression

‹

FOLR1 overexpression (6)

FOLR1 positive (5)

FOLR1 positive + TRPV6 positive (1)

FOLR1 overexpression (6)

FOLR1 positive (5)

FOLR1 positive + TRPV6 positive (1)

›

Related tests:

VENTANA FOLR1 RxDx Assay (5)

FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Fallopian Tube Cancer	FOLR1 expression	Fallopian Tube Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Peritoneal Cancer	FOLR1 expression	Peritoneal Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Peritoneal Cancer	FOLR1 expression	Peritoneal Cancer	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Fallopian Tube Cancer	FOLR1 expression	Fallopian Tube Cancer	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2	mirvetuximab soravtansine-gynx Sensitive: A2 - Guideline mirvetuximab soravtansine-gynx Sensitive : A2
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	STRO-002 Sensitive: C2 – Inclusion Criteria STRO-002 Sensitive : C2	STRO-002 Sensitive: C2 – Inclusion Criteria STRO-002 Sensitive : C2
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	PRO1184 Sensitive: C2 – Inclusion Criteria PRO1184 Sensitive : C2	PRO1184 Sensitive: C2 – Inclusion Criteria PRO1184 Sensitive : C2
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials mirvetuximab soravtansine-gynx Sensitive : C3	mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials mirvetuximab soravtansine-gynx Sensitive : C3
FOLR1 expression	Solid Tumor	FOLR1 expression	Solid Tumor	MORAb-202 Sensitive: C3 – Early Trials MORAb-202 Sensitive : C3	MORAb-202 Sensitive: C3 – Early Trials MORAb-202 Sensitive : C3
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3	rucaparib + mirvetuximab soravtansine-gynx Sensitive: C3 – Early Trials rucaparib + mirvetuximab soravtansine-gynx Sensitive : C3
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	CT900 Sensitive: C3 – Early Trials CT900 Sensitive : C3	CT900 Sensitive: C3 – Early Trials CT900 Sensitive : C3
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	STRO-002 Sensitive: C3 – Early Trials STRO-002 Sensitive : C3	STRO-002 Sensitive: C3 – Early Trials STRO-002 Sensitive : C3
FOLR1 expression	Acute Myelogenous Leukemia	FOLR1 expression	Acute Myelogenous Leukemia	ELU001 Sensitive: D – Preclinical ELU001 Sensitive : D	ELU001 Sensitive: D – Preclinical ELU001 Sensitive : D
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	AZD5335 Sensitive: D – Preclinical AZD5335 Sensitive : D	AZD5335 Sensitive: D – Preclinical AZD5335 Sensitive : D
FOLR1 expression	Non Small Cell Lung Cancer	FOLR1 expression	Non Small Cell Lung Cancer	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D	bevacizumab + STRO-002 Sensitive: D – Preclinical bevacizumab + STRO-002 Sensitive : D
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	ZW191 Sensitive: D – Preclinical ZW191 Sensitive : D	ZW191 Sensitive: D – Preclinical ZW191 Sensitive : D
FOLR1 expression	Endometrial Cancer	FOLR1 expression	Endometrial Cancer	MORAb-202 Sensitive: D – Preclinical MORAb-202 Sensitive : D	MORAb-202 Sensitive: D – Preclinical MORAb-202 Sensitive : D

FOLR1 expression

Associations